UNSPSC 51422403: Anecortave

This classification denotes an angiogenesis inhibitor with the molecular formula C21H28O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R5Y8O51589, chemically known as 17-alpha,21-dihydroxypregna-4,9(11)-diene-3,20-dione 21-acetate but generally known as anecortave, which bears US NIH Compound Identifier 111332. anecortave most often comes in base and acetate forms. World Health Organization schedules anecortave in its Anatomical Therapeutic Chemical (ATC) Classification.

Most nations schedule anecortave under HS 29372900 and SITC 54153. As of Q4 2014, ANECORTAVE remains the US FDA Preferred Term for this commodity. SMILES: CC(=O)OCC(=O)C1(CCC2C1(CC=C3C2CCC4=CC(=O)CCC43C)C)O.

UNSPSC 51422403 Anecortave is a Commodity code for pharmaceutical products, but the recent state and local procurement activity under this code bears no relationship to anecortave specifically. Seminole County, Florida posted an IFB in June 2026 for naloxone and drug deactivation systems—opioid-antagonist medications and harm-reduction equipment—unrelated to the code's nominal scope. State and local procurement systems occasionally misclassify opportunities by commodity code, and this entry appears to reflect such a mismatch. The code shows no verifiable recent activity aligned with its stated pharmaceutical category.

The single opportunity on record—Seminole County's IFB 60459723LAS, due July 26, 2026—solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually for quarterly delivery to the Seminole County Community Health Building in Sanford, Florida. The procurement was structured as a competitive bid with a two-year initial term and one-year renewal option, with E-Verify and drug-free workplace certification required. Because the opportunity posted under this code does not match its pharmaceutical definition, business development professionals should verify the correct UNSPSC classification for opioid-antagonist and harm-reduction products before pursuing similar community health initiatives in Florida or elsewhere.